Despite a strong need for drugs treating schizophrenia and Parkinson’s, ACADIA Pharmaceuticals (ACAD) is still slumping on the markets.Mentions for the two illnesses spiked in September, around the time when ACAD stock traded at $35 per share. It looks as if Acadia would hold its value on the markets despite a new CFO joining in August. The hire happened because the company raised new capital, was readying to launch a new product, and was positioned to grow revenue.Source: https://www.tickertags.com/ The launch of Nuplazid should excite investors, so the steady drop suggests other negative pressures are at play. The drug will sell wholesale for $23,400 per patient annually. The TAM is in the millions but watch ADP III results first. Only then will investors know if the drug will be a blockbuster.The biotech sector is performing poorly as investors ready themselves for the unknown, ahead of Americans casting their vote at the U.S. elections in November.Watch the biotech index (IBB) in the interim. The sector is down ~ 20 percent in the last year.